Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

92.41USD
26 Jun 2019
Change (% chg)

$-0.78 (-0.84%)
Prev Close
$93.19
Open
$93.56
Day's High
$93.75
Day's Low
$92.02
Volume
1,933,335
Avg. Vol
2,052,556
52-wk High
$98.97
52-wk Low
$58.61

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $65,723.13
Shares Outstanding(Mil.): 705.26
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 14.30 32.49 37.22
EPS (TTM): 6.52 -- --
ROI: 14.44 12.55 12.18
ROE: 70.51 13.86 17.03

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion (£49.6 billion), giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

25 Jun 2019

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.

25 Jun 2019

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

25 Jun 2019

Deals of the day-Mergers and acquisitions

June 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

24 Jun 2019

US STOCKS-Wall St flat as healthcare losses limit tech gains

* Dow up 0.17%, S&P flat, Nasdaq off 0.04% (Updates to early afternoon)

24 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

24 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion (58 billion pounds) deal.

24 Jun 2019

UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

June 24 Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.

24 Jun 2019

US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses

* Indexes up: Dow 0.19%, S&P 0.10%, Nasdaq 0.04% (Updates prices, comments)

24 Jun 2019

US STOCKS-Wall Street edges higher as tech offsets healthcare loss

* Dow up 0.23%, S&P rises 0.11%, Nasdaq inches 0.06% higher (Updates to open)

24 Jun 2019

Earnings vs. Estimates